Open AccessEfficacy and safety of amurubicin for the elderly patients with refractory relapsed small cell lung cancer as third-line chemotherapy
Author(s) -
Nobuhiro Asai,
Yoshihiro Ohkuni,
Ryo Matsunuma,
Kei Nakashima,
Takuya Iwasaki,
Norihiro Kaneko
Publication year - 2012
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.98983
Subject(s) - medicine , refractory (planetary science) , chemotherapy , lung cancer , retrospective cohort study , oncology , cancer , surgery , astrobiology , physics
While more elderly patients are being diagnosed with lung cancer every year, no anti-lung cancer therapy designed specifically for the elderly has been established yet. This is the first retrospective study to examine the efficacy and safety of amurubicin (AMR) for elderly patients with refractory relapsed small cell lung cancer (SCLC) as second or third-line chemotherapy.